A key thing to watch is OTC Markets filings or updates. RVUE is expected to at least file unaudited numbers on it or face delisting of the common stock by the SEC. If Roche has more serious plans here then filing with OTC Markets would not be in the playbook. Or at least that is my theory. One thing for certain is all Roche has here is common stock and protecting the longevity of it should be a priority (despite the temporary value of the pps). We have all agreed that the asset value here was not worth his price to take the goods and run.